WEBULL
WebtradeDownload

Why Did Indivior Pharmaceuticals (INDV) Stock Slide And What Is Behind It?

Simply Wall St · 2d ago

Indivior Pharmaceuticals (INDV) has drawn attention after a recent share price slide, with the stock down 3.5% on the day and 9.4% over the past week.

That slide comes after a weaker stretch, with the 30-day share price return down 5.53% and the 90-day share price return down almost 20%. However, the 1-year total shareholder return of 32.56% shows Indivior Pharmaceuticals has still rewarded investors over a longer holding period.

Broaden your watchlist beyond Indivior Pharmaceuticals by checking hand-picked pharmaceutical peers with solid fundamentals through the list of solid balance sheet and fundamentals (25 results).

Bulls see Indivior Pharmaceuticals as a growing OUD specialist on sale after a sharp pullback. Bears argue the slide flags deeper risks. Which side does current valuation actually support next?

Most Popular Narrative: 36% Undervalued

On the most followed view of Indivior Pharmaceuticals, a fair value of about $50.83 sits well above the recent $32.45 close. This frames the latest pullback as a valuation gap rather than just a sentiment swing.

The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.

See why 6 investors see Indivior Pharmaceuticals as 36% undervalued.

Result: Fair Value of $50.83 (UNDERVALUED)

Still, the narrative could be challenged if SUBLOCADE uptake slows or if cost savings under the Indivior Action Agenda prove harder to realize.

Find out about the key risks to this Indivior Pharmaceuticals narrative.

Next Steps

Mixed headlines around Indivior Pharmaceuticals can make the story feel muddled, so check the full scorecard and weigh both the risks and the upside in the 5 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Indivior Pharmaceuticals?

Do not stop at Indivior Pharmaceuticals when the wider market may hold opportunities that fit your risk profile and income goals just as well.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.